Dr. Paul Janssen award voor het eerst naar een Belg: http://tiny.cc/kz3u2
posted 11 hours ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Galapagos NV (Euronext: GLPG) announced today that it has successfully identified a third candidate drug in its arthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached milestones for other compounds in the alliance. Together, these milestones trigger cash payments totaling €5.7 million to Galapagos.
This latest pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate against a novel drug target from its proprietary platform. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials early 2011.
“We are proud to deliver the third candidate drug in the arthritis alliance with GSK,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “Multiple candidates provide more shots on goal in terms of getting a drug to the market. It is gratifying that our discovery organization has been so successful in this alliance.”
Source: Galapagos
Bookmark this:
